Randomized Phase II Cancer Clinical Trials
β Scribed by Sin-Ho Jung
- Publisher
- Chapman and Hall/CRC
- Year
- 2013
- Tongue
- English
- Leaves
- 236
- Series
- Chapman & Hall/CRC Biostatistics Series
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
In cancer research, a traditional phase II trial is designed as a single-arm trial that compares the experimental therapy to a historical control. This simple trial design has led to several adverse issues, including increased false positivity of phase II trial results and negative phase III trials. To rectify these problems, oncologists and biostatisticians have begun to use a randomized phase II trial that compares an experimental therapy with a prospective control therapy.
Randomized Phase II Cancer Clinical Trials explains how to properly select and accurately use diverse statistical methods for designing and analyzing phase II trials. The author first reviews the statistical methods for single-arm phase II trials since some methodologies for randomized phase II trials stem from single-arm phase II trials and many phase II cancer clinical trials still use single-arm designs. The book then presents methods for randomized phase II trials and describes statistical methods for both single-arm and randomized phase II trials. Although the text focuses on phase II cancer clinical trials, the statistical methods covered can also be used (with minor modifications) in phase II trials for other diseases and in phase III cancer clinical trials.
Suitable for cancer clinicians and biostatisticians, this book shows how randomized phase II trials with a prospective control resolve the shortcomings of traditional single-arm phase II trials. It provides readers with numerous statistical design and analysis methods for randomized phase II trials in oncology.
β¦ Table of Contents
Introduction
Single-Arm Phase II Trial Designs
Single-Stage Designs
Two-Stage Designs
Two-Stage Designs with Both Upper and Lower Stopping Values
Inference on the Binomial Probability in Single-Arm Multistage Clinical Trials
Point Estimation
Confidence Intervals
P-Values
When Realized Sample Size Is Different from That Specified in Design
Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints
A Test Based on Median Survival Time
Maximum Likelihood Method for Exponential Distribution
One-Sample Log-Rank Test
Two-Stage Trials Using One-Sample Log-Rank Test
Binomial Testing on t-Year Survival Probability
Single-Arm Phase II Trials with Heterogeneous Patient Populations: Binary and Survival Outcomes
Binary Outcome Case
Survival Outcome Case: Stratified One-Sample Log-Rank Test
Randomized Phase II Trials for Selection: No Prospective Control Arms
With a Historical Control
When No Historical Control Exists
Extension to More Than Two Arms
Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (I): Two-Sample Binomial Test
Two-Sample Binomial Test
Two-Stage Designs with Both Upper and Lower Stopping Values
Discussions
Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (II): Fisherβs Exact Test
Single-Stage Design
Two-Stage Design
Extensions
Discussions
Randomized Phase II Trials with Heterogeneous Patient Populations: Stratified Fisherβs Exact Test
Single-Stage Stratified Fisherβs Exact Test
Two-Stage Designs with an Interim Futility Test
Randomized Phase II Clinical Trials Based on Survival Endpoints: Two-Sample Log-Rank Test
Two-Sample Log-Rank Test
Two-Stage Log-Rank Test
Stratified Two-Sample Log-Rank Test for Single-Stage Designs
Some Flexible Phase II Clinical Trial Designs
Comparing Survival Distributions under General Hypothesis Testing
Randomized Phase II Trials for Comparing Maintenance Therapies
Index
References appear at the end of each chapter.
π SIMILAR VOLUMES
Phase I trials are a critical first step in the study of novel cancer therapeutic approaches. Their primary goals are to identify the recommended dose, schedule and pharmacologic behavior of new agents or new combinations of agents and to describe the adverse effects of treatment. In cancer therapeu
<p>The controlled clinical trial has become an essential part of the clinician's decision-making process. Clinical trials, however, still raise methodological problems that are important and at the same time controversial: subgroup analysis and interactions, meta-analyΒ sis of similar trials, consid
<p>After 13 years there are new areas to discuss and more recent trials to be included. Good clinical practice; evaluation of quality of life; measurement of the benefit:risk comparison; determination of cost- effectiveness and cost utility; stopping rules for trials; meta-analysis and subgroup anal
<p>Bradford Hill has defined a clinical trial as "A carefully and ethically designed experiment with the aim of answering some precisely framed question" [1]. This definition specifies a careful design and requires the provision of adequate controls. Random allocation of treatments to subjects is im